Vulvovaginal Candidiasis: Antifungal Pharmacotherapy
Core concept: Symptomatic vulvovaginal candidiasis (VVC) is usually treated with an azole antifungal, but complicated or recurrent disease requires species-aware evaluation.
Key clinical distinction: Uncomplicated VVC, pregnancy-associated VVC, and non-albicans or recurrent VVC are not interchangeable treatment scenarios.
Prescribing priority: Confirm symptoms and risk factors, exclude common mimics, and avoid unnecessary systemic azoles, especially in pregnancy (Ballou & Miller, 2026; Stone, 2026).
Clinical assessment and confirmation
Pruritus, vulvar erythema, dysuria localized to irritated skin, dyspareunia, and thick discharge suggest VVC. Vaginal pH is usually in the normal acidic range. Microscopy showing budding yeast or hyphae supports the diagnosis, but a negative wet mount does not exclude infection. Culture or molecular identification is valuable for severe, persistent, recurrent, or non-albicans disease. Asymptomatic Candida colonization should not routinely be treated. Consider BV, trichomoniasis, dermatitis, and genital herpes when symptoms are atypical (Ballou & Miller, 2026).
Uncomplicated treatment
Fluconazole 150 mg orally once is an option for nonpregnant patients with uncomplicated VVC and no relevant contraindication or interaction. Intravaginal azole choices include clotrimazole, miconazole, terconazole, and other labeled preparations with product-specific one-, three-, or seven-day regimens. Counseling should cover local irritation, possible barrier-latex weakening with oil-based vaginal products, and the fact that oral fluconazole may have substantial CYP-mediated interactions. Patient preference, cost, formulation, and prior response matter (Ballou & Miller, 2026).
Severe, recurrent, and non-albicans disease
Severe infection may require a longer topical course or additional appropriately spaced oral fluconazole in a nonpregnant patient. Recurrent VVC typically requires confirmation, species identification as indicated, induction therapy, and then a maintenance strategy (commonly weekly fluconazole for six months when C. albicans is susceptible and the patient is eligible). Symptom recurrence shortly after OTC treatment warrants evaluation rather than repeated unsupervised antifungal courses. Candida glabrata and other non-albicans species may be less responsive to standard fluconazole. Culture susceptibility and specialist input are appropriate when resistance is suspected (Ballou & Miller, 2026).
Pregnancy and partner management
During pregnancy, use a topical azole for seven days rather than oral fluconazole. In lactation, medication choice depends on formulation and infant factors. Routine treatment of asymptomatic sexual partners is generally unnecessary, because uncomplicated VVC is not usually sexually transmitted. Evaluate diabetes control or immunosuppression when recurrent infection raises concern for a contributory condition (Stone, 2026; Ballou & Miller, 2026).
Choose induction versus maintenance using disease phenotype
Uncomplicated nonpregnant VVC can be treated with a single oral fluconazole 150-mg dose or an appropriate short-course intravaginal azole. Severe inflammatory VVC may require a longer topical regimen or an additional oral dose 72 hours later. Recurrent proven Candida albicans VVC requires induction sufficient to achieve mycologic remission, then fluconazole 100–200 mg orally weekly for six months when appropriate. Maintenance suppresses recurrence but is not a permanent cure. Culture/speciation, adherence assessment, and susceptibility testing become important with symptoms persisting on maintenance (Ballou & Miller, 2026).
An organism change alters drug choice
In non-albicans VVC, particularly with C. glabrata, single-dose fluconazole is often inadequate. CDC recommends seven to 14 days of a nonfluconazole azole regimen for symptomatic non-albicans VVC, then—if recurrence is confirmed—boric acid 600 mg vaginally daily for three weeks as an option with limited evidence (about 70% eradication in the cited evidence). Boric acid must never be taken orally and is inappropriate in pregnancy; ensure safe storage away from children and specialist consultation for persistent disease. CDC recommends topical azoles for seven days in pregnancy rather than oral fluconazole. For recurrent C. albicans VVC, establish remission with a longer induction before fluconazole maintenance, usually weekly for six months if appropriate, while reviewing drug interactions and liver safety (CDC, 2021, Vulvovaginal Candidiasis).
Clinical application
A nonpregnant patient has four culture-proven Candida albicans episodes within a year and is currently symptomatic despite intermittent single-dose fluconazole. Confirm species, pregnancy possibility, adherence, and interacting drugs; distinguish a new isolated episode from recurrent disease requiring induction plus weekly maintenance for six months. At follow-up, document symptom control and whether infection remains culture-positive; persistent disease warrants susceptibility assessment. The same plan would not apply in pregnancy or proven C. glabrata infection (Ballou & Miller, 2026).
High-yield distinctions
Symptoms alone cannot reliably separate VVC from other vaginitis causes. A single oral fluconazole dose is not the default choice in pregnancy. A persistent positive culture without symptoms does not automatically justify additional medication.
Related YourDNP Resources
Pharmacology learning hub · Bacterial vaginosis · Trichomoniasis · Antifungal pharmacology essentials
Content last reviewed:
References
Ballou, J. M., & Miller, L. E. (2026). Superficial fungal infections. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., Chapter 85). McGraw Hill.
Centers for Disease Control and Prevention. (2021). Vulvovaginal candidiasis. STI treatment guidelines. https://www.cdc.gov/std/treatment-guidelines/candidiasis.htm
Stone, R. H. (2026). Pregnancy and lactation: Therapeutic considerations. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., Chapter 48). McGraw Hill.